Does the media refer more to HRTX or DERM?

In the previous week, Journey Medical had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Journey Medical and 2 mentions for Heron Therapeutics. Journey Medical's average media sentiment score of 0.70 beat Heron Therapeutics' score of 0.65 indicating that Journey Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Journey Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACOG or HRTX?

In the previous week, Alpha Cognition and Alpha Cognition both had 2 articles in the media. Heron Therapeutics' average media sentiment score of 0.65 beat Alpha Cognition's score of 0.42 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HRTX or ANTX more profitable?

Anthem has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Anthem's return on equity of -53.52% beat Heron Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Heron Therapeutics -22.52% -293.02% -10.00% Anthem N/A -53.52% -48.63%

Does the media refer more to HRTX or SLGL?

In the previous week, Sol-Gel Technologies had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.65 beat Sol-Gel Technologies' score of 0.31 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sol-Gel Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Heron Therapeutics (HRTX) Competitors

$0.29 0.00 (-0.34%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$0.29 0.00 (-1.38%)

As of 09/24/2026 07:32 PM Eastern

Compare

HRTX vs. DERM, ACOG, ANTX, NERV, and SLGL

Should you buy Heron Therapeutics stock or one of its competitors? Heron Therapeutics's main competitors and comparable companies include Journey Medical (DERM), Alpha Cognition (ACOG), Anthem (ANTX), Minerva Neurosciences (NERV), and Sol-Gel Technologies (SLGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Heron Therapeutics compare to Journey Medical?

Heron Therapeutics (NASDAQ:HRTX) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Heron Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

In the previous week, Journey Medical had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Journey Medical and 2 mentions for Heron Therapeutics. Journey Medical's average media sentiment score of 0.70 beat Heron Therapeutics' score of 0.65 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Journey Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Journey Medical has a net margin of -8.95% compared to Heron Therapeutics' net margin of -22.52%. Journey Medical's return on equity of -20.23% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Journey Medical	-8.95%	-20.23%	-6.60%

Heron Therapeutics currently has a consensus target price of $2.00, suggesting a potential upside of 589.66%. Journey Medical has a consensus target price of $14.00, suggesting a potential upside of 121.52%. Given Heron Therapeutics' higher probable upside, research analysts plainly believe Heron Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Journey Medical has lower revenue, but higher earnings than Heron Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.36	-$20.19M	-$0.19	N/A
Journey Medical	$61.86M	2.88	-$11.43M	-$0.22	N/A

Summary

Journey Medical beats Heron Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

80.0% of Heron Therapeutics shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alpha Cognition currently has a consensus target price of $18.00, indicating a potential upside of 110.04%. Heron Therapeutics has a consensus target price of $2.00, indicating a potential upside of 589.66%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alpha Cognition has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

Heron Therapeutics has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	18.26	-$20.67M	-$1.10	N/A
Heron Therapeutics	$154.90M	0.36	-$20.19M	-$0.19	N/A

In the previous week, Alpha Cognition and Alpha Cognition both had 2 articles in the media. Heron Therapeutics' average media sentiment score of 0.65 beat Alpha Cognition's score of 0.42 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Heron Therapeutics has a net margin of -22.52% compared to Alpha Cognition's net margin of -153.61%. Alpha Cognition's return on equity of -54.60% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-54.60%	-43.47%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

Summary

Heron Therapeutics beats Alpha Cognition on 9 of the 15 factors compared between the two stocks.

How does Heron Therapeutics compare to Anthem?

Heron Therapeutics (NASDAQ:HRTX) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Heron Therapeutics has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.36	-$20.19M	-$0.19	N/A
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

In the previous week, Heron Therapeutics had 1 more articles in the media than Anthem. MarketBeat recorded 2 mentions for Heron Therapeutics and 1 mentions for Anthem. Heron Therapeutics' average media sentiment score of 0.65 beat Anthem's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Positive
Anthem	Neutral

Anthem has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Anthem's return on equity of -53.52% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Anthem	N/A	-53.52%	-48.63%

Heron Therapeutics presently has a consensus price target of $2.00, indicating a potential upside of 589.66%. Anthem has a consensus price target of $9.00, indicating a potential upside of 84.05%. Given Heron Therapeutics' higher possible upside, research analysts clearly believe Heron Therapeutics is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by insiders. Comparatively, 22.6% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Heron Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Anthem has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

Summary

Heron Therapeutics beats Anthem on 9 of the 15 factors compared between the two stocks.

How does Heron Therapeutics compare to Minerva Neurosciences?

Heron Therapeutics (NASDAQ:HRTX) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Minerva Neurosciences has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Minerva Neurosciences' return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Minerva Neurosciences	N/A	N/A	-31.72%

Heron Therapeutics has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market.

Heron Therapeutics currently has a consensus target price of $2.00, indicating a potential upside of 589.66%. Minerva Neurosciences has a consensus target price of $10.33, indicating a potential upside of 199.52%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Heron Therapeutics has higher revenue and earnings than Minerva Neurosciences. Heron Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.36	-$20.19M	-$0.19	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

In the previous week, Heron Therapeutics had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for Heron Therapeutics and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.79 beat Heron Therapeutics' score of 0.65 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Heron Therapeutics	Positive
Minerva Neurosciences	Very Positive

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Heron Therapeutics beats Minerva Neurosciences on 10 of the 14 factors compared between the two stocks.

How does Heron Therapeutics compare to Sol-Gel Technologies?

Heron Therapeutics (NASDAQ:HRTX) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Sol-Gel Technologies had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.65 beat Sol-Gel Technologies' score of 0.31 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sol-Gel Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Heron Therapeutics has a net margin of -22.52% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Heron Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Heron Therapeutics currently has a consensus target price of $2.00, suggesting a potential upside of 589.66%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 225.16%. Given Heron Therapeutics' higher probable upside, equities research analysts clearly believe Heron Therapeutics is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sol-Gel Technologies has lower revenue, but higher earnings than Heron Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.36	-$20.19M	-$0.19	N/A
Sol-Gel Technologies	$19.39M	8.80	-$6.13M	-$5.64	N/A

Summary

Heron Therapeutics beats Sol-Gel Technologies on 9 of the 17 factors compared between the two stocks.

Get Heron Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRTX vs. The Competition

Export

Metric	Heron Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$56.77M	$12.62B	$7.32B	$13.29B
Dividend Yield	N/A	2.62%	2.52%	12.57%
P/E Ratio	-1.53	789.89	274.40	25.76
Price / Sales	0.36	1,003.44	688.47	106.32
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	4.14	10.69	10.52	6.34
Net Income	-$20.19M	$2.83B	$3.49B	$360.00M
7 Day Performance	-6.36%	-0.50%	-0.94%	-0.16%
1 Month Performance	-10.24%	-2.33%	-4.24%	-4.07%
1 Year Performance	-76.23%	3.19%	16.39%	5.97%

Heron Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRTX Heron Therapeutics	2.0077 of 5 stars	$0.29 -0.3%	$2.00 +589.7%	-76.8%	$56.77M	$154.90M	N/A	128
DERM Journey Medical	2.2044 of 5 stars	$7.08 +1.3%	$14.00 +97.7%	-12.2%	$199.77M	$61.86M	N/A	58
ACOG Alpha Cognition	3.9841 of 5 stars	$8.95 -0.3%	$18.00 +101.2%	+7.1%	$194.82M	$10.22M	N/A	71
ANTX Anthem	1.7407 of 5 stars	$4.77 -3.8%	$9.00 +88.7%	+284.7%	$180.02M	N/A	N/A	N/A
NERV Minerva Neurosciences	1.7615 of 5 stars	$3.74 +1.6%	$10.33 +176.3%	+57.5%	$178.58M	N/A	N/A	7	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRTX) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heron Therapeutics (HRTX) Competitors

HRTX vs. DERM, ACOG, ANTX, NERV, and SLGL

How does Heron Therapeutics compare to Journey Medical?

Summary

How does Heron Therapeutics compare to Alpha Cognition?

Summary

How does Heron Therapeutics compare to Anthem?

Summary

How does Heron Therapeutics compare to Minerva Neurosciences?

Summary

How does Heron Therapeutics compare to Sol-Gel Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heron Therapeutics (HRTX) Competitors

HRTX vs. DERM, ACOG, ANTX, NERV, and SLGL

How does Heron Therapeutics compare to Journey Medical?

Do insiders & institutionals have more ownership in HRTX or DERM?

Which has more volatility & risk, HRTX or DERM?

Does the media refer more to HRTX or DERM?

Is HRTX or DERM more profitable?

Do analysts rate HRTX or DERM?

Which has preferable valuation and earnings, HRTX or DERM?

Summary

How does Heron Therapeutics compare to Alpha Cognition?

Do insiders and institutionals believe in ACOG or HRTX?

Do analysts rate ACOG or HRTX?

Which has more volatility and risk, ACOG or HRTX?

Which has higher valuation and earnings, ACOG or HRTX?

Does the media favor ACOG or HRTX?

Is ACOG or HRTX more profitable?

Summary

How does Heron Therapeutics compare to Anthem?

Which has preferable valuation & earnings, HRTX or ANTX?

Does the media favor HRTX or ANTX?

Is HRTX or ANTX more profitable?

Do analysts recommend HRTX or ANTX?

Do insiders & institutionals believe in HRTX or ANTX?

Which has more volatility & risk, HRTX or ANTX?

Summary

How does Heron Therapeutics compare to Minerva Neurosciences?

Is HRTX or NERV more profitable?

Which has more risk and volatility, HRTX or NERV?

Do analysts recommend HRTX or NERV?

Which has stronger earnings and valuation, HRTX or NERV?

Does the media favor HRTX or NERV?

Do institutionals and insiders believe in HRTX or NERV?

Summary

How does Heron Therapeutics compare to Sol-Gel Technologies?

Does the media refer more to HRTX or SLGL?

Is HRTX or SLGL more profitable?

Which has more volatility & risk, HRTX or SLGL?

Do analysts recommend HRTX or SLGL?

Do institutionals and insiders hold more shares of HRTX or SLGL?

Which has preferable valuation and earnings, HRTX or SLGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools